Caristo was founded in 2018 by Cardiologists at the University of Oxford, following a decade of scientific research and technical development, and is now a leader in supporting the transformation of healthcare from treatment-based medicine to prevention. Caristo’s technology aims to revolutionise diagnosis and treatment, enabling physicians to identify patients with the highest heart attack risk and prescribe effective, personalised treatments that can prevent a fatal heart attack.
To date the company has raised a total of £10.2 million, they recently closed a successful investment round led by BGF and existing investors including Oxford Sciences Innovation (OSI), Longwall Ventures and the Oxford Technology & Innovation Fund (OTIF).
New products in the pipeline will also be capable of predicting stroke and diabetes risk, years in advance.
Business funding insights
BGF explains: initial public offerings (IPOs)
We explain what’s meant by an initial public offering (IPO), also known as listing or ‘going public’.
When to pursue debt refinancing and why
You may find that refinancing or renegotiating your business debts can put you in a stronger financial position. Look at…